BS RAWAT
NEW DELHI : The National Pharmaceutical Pricing Authority (NPPA) has drastically reduced the maximum retail price of 463 non-scheduled cancer medicines. The NPPA has done this through an office memorandum which is in continuation of its earlier office memorandum dated March 8, 2019, by which some 390 cancer drugs' prices were slashed.

The NPPA has issued the list of the 463 non-scheduled anti-cancer drugs whose prices have been drastically reduced through trade margin rationalization under paragraph 19 of DPCO, 2013 on the data provided by manufacturers with additional details of pack size.

The memorandum revising the prices downwards has been issued by NPPA's Director (Pricing), Amarpal Singh Sawhney, on March 11, 2019.

Manufacturers and hospitals were directed to convey the revised MRP, to be effective immediately based on the trade margin formula.